Does Cosentyx Cause New Side Effects with Long-Term Use?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows side effects that remain consistent over extended use, with no unique profile emerging beyond the first year. Clinical trials and post-marketing data indicate infections (upper respiratory, urinary tract) and diarrhea occur at similar rates long-term as initially, typically 10-20% incidence.[1][2] Candida infections may slightly increase with duration due to immune modulation but stay under 5%.[1]
Which Side Effects Show Up Most in Long-Term Studies?
In the FUTURE and MEASURE trials (up to 5 years), common events included nasopharyngitis (15-25%), diarrhea (10-15%), and upper respiratory infections (10-20%), with rates plateauing after year 1.[2] Serious infections dropped over time with monitoring. No dose-dependent escalation for hypersensitivity or IBD flares.[1][3] Novartis reports from 10-year data confirm this stability, attributing it to the drug's targeted mechanism.[2]
How Do Short-Term and Extended Use Side Effects Compare?
| Duration | Common Side Effects (>5%) | Serious Events (e.g., Infections <1%) |
|----------|----------------------------|--------------------------------------|
| First 12 months | Nasopharyngitis (20%), diarrhea (12%), bronchitis (7%) | Opportunistic infections (0.5%)[1] |
| 2-5 years | Similar rates; slight candida uptick (3-4%) | Declines with prophylaxis[2] |
Short-term aligns with long-term, per FDA label and EU summaries—no cumulative worsening.[1][3]
What Risks Increase Over Time and How to Manage Them?
IBD (Crohn's/ulcerative colitis) risk, rare overall (0.1-0.4%), prompts screening before starting and monitoring indefinitely, as cases can emerge later.[1] MACE (cardiovascular events) saw no rise in 5-year data.[2] Vaccinations and infection vigilance mitigate most issues; discontinuations for AEs drop from 5% year 1 to <2% long-term.[2]
Patient Reports vs. Clinical Data on Long-Term Use
Real-world registries (e.g., BADBIR, CorEvitas) mirror trials: 70-80% maintain response at 3-5 years with stable tolerability; patient forums note fatigue or injection-site reactions persisting but not intensifying.[4] No widespread reports of novel long-term effects like malignancy spikes beyond baseline.
[1]: FDA Cosentyx Label
[2]: Novartis Cosentyx 5-Year Data
[3]: EMA Cosentyx Summary
[4]: DrugPatentWatch.com - Cosentyx Safety